Trials / Completed
CompletedNCT00410306
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
International, Multi-center Post Authorization Surveillance Study on the Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,493 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational study with a drug called Nebido, a new testosterone replacement therapy, which is available for the treatment of male hypogonadism. The benefit and safety of Nebido have already been thoroughly evaluated through well controlled clinical trials. The main purpose of this observational study is to confirm the established safety profile of Nebido in daily clinical practice.
Detailed description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Testosterone Undecanoate (Nebido, BAY86-5037) | Patients from routine practice |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2006-12-12
- Last updated
- 2010-09-24
Locations
33 sites across 33 countries: Australia, Austria, Bulgaria, Colombia, Czechia, Estonia, Germany, Hong Kong, Indonesia, Italy, Jordan, Kazakhstan, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, North Macedonia, Philippines, Romania, Russia, Saudi Arabia, Singapore, Slovenia, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00410306. Inclusion in this directory is not an endorsement.